Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.2020 European PRRS Research Award sponsorship
2020 European PRRS Research Award: Boehringer Ingelheim calls for submissionsBoehringer Ingelheim funds three research projects for improved control of swine disease PRRS with a total of 75,000 eurosThis Award aims at encouraging research and enhancing the interaction among swine researchers and veterinarians (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2020 Category: Research Source Type: news
FOYA_Shanghai
Boehringer Ingelheim Biopharmaceuticals China receives “Facility of the Year” AwardBoehringer Ingelheim ’s commercial manufacturing site OASIS in Shanghai has been honored with an award in the ‘Facility of the Year’ programThe International Society for Pharmaceutical Engineering has awarded the company the prize with an ' Honorable Mention 'The facility impresses with its flexible and well thought-out concept (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 9, 2020 Category: Research Source Type: news
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Solid performance in previous years strengthened the basis for absorbing the effects of COVID-19 spreading; production continues at a high levelStrong development pipeline; 18.2% of net sales invested in R&DGlobal Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 8, 2020 Category: Research Source Type: news
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support ProgramGlobal support fund for local relief increased to EUR 5.8 millionOver 100 scientists and 11,000 lab hours committed to COVID-19 research in international consortia, expected to expand10 days paid leave offered to 51,000 employees for volunteeringEUR 580,000 relief fund made available for Making More Health communities and social entrepreneurs in India and Kenya (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 8, 2020 Category: Research Source Type: news
BI_X_Shanghai
Boehringer Ingelheim opens second branch of digital lab BI X in ShanghaiInitial investment of 3 million euros for tailored digital solutions focusing Chinese patients and customers20 new jobs for digital talents Close collaboration between BI X China and BI X GermanyBoehringer Ingelheim is among the first wave of pharmaceutical companies to build a dedicated digital innovation business in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 30, 2020 Category: Research Source Type: news
Fda-crl-t1d
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2020 Category: Research Source Type: news
Uncommon_Mutations_Database
New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib New searchable database of published clinical outcomes from patients with uncommon EGFR mutations in advanced/metastatic NSCLC treated with afatinib, reported by individual mutation, is available for global clinician use at:www.uncommonEGFRmutations.comPooled analysis of 693 NSCLC patient cases published in the Journal of Thoracic Oncology (JTO) supports the use of afatinib against the most prevalent uncommon EGFR mutations (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 16, 2020 Category: Research Source Type: news
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the ' Ruminant Well-Being Awards ’Boehringer Ingelheim demonstrates the long-term commitment for animal well-being by supporting these biennial awardsThe winner in each of the two awards will receive 10,000 euro (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 16, 2020 Category: Research Source Type: news
FDA-Fast-Track-chronic-kidney-disease
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2020 Category: Research Source Type: news
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the treatment ...
Source: Boehringer Ingelheim Corporate News - February 28, 2020 Category: Research Source Type: news
cytokine platform collaboration with trutino biosciences
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine PlatformBoehringer Ingelheim will work with Trutino Biosciences to access the company ’s On-Demand-CytokineTM (ODC) platform to develop new cancer immunology compoundsThe partners aim to develop safer, more tolerable and more effective cytokine therapies for single agent and novel combinations with Boehringer Ingelheim ’s innovative cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapies (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 27, 2020 Category: Research Source Type: news
MyStudyWindow
Boehringer Ingelheim Launches Patient-Centric MyStudyWindow Powered by CareboxBoehringer Ingelheim offers MyStudyWindow to provide patients, families, caregivers, and doctors consistent access to information about Boehringer Ingelheim ’s actively recruiting studies conducted at global site locationsThe platform features patient-centric study titles and descriptions, educational content, and guidance on the clinical trial selection and enrollment process Anonymous condition-based questionnaires identify and pre-screen potentially relevant studies based on a few questions about patient diagnosis, disease stage, and treat...
Source: Boehringer Ingelheim Corporate News - February 18, 2020 Category: Research Source Type: news
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-beingBoehringer Ingelheim launches an innovative project to better understand human behaviors associated with pain management in cattle This project attests to the company ’s long-term commitment to farm animal well-being (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 17, 2020 Category: Research Source Type: news
CARMELINA-elderly-analysis
CARMELINA ® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes Linagliptin did not increase the risk of adverse cardiovascular events, hospitalization for heart failure or adverse kidney events compared with placebo in older people with type 2 diabetes in a prespecified subgroup analysis of the CARMELINA ® cardiovascular outcome trial1In addition, linagliptin did not increase the risk of hypoglycemia compared with placebo in this population1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 12, 2020 Category: Research Source Type: news
Respimat re-usable wins Pharmapack Eco-Design Award
Respimat ® re-usable inhaler wins 2020 Pharmapack Eco-Design AwardRespimat ® re-usable has a lower carbon footprint and reduces waste compared with single-use inhalers1,2,3The device has been designed with patient input and contains features that improve ease of handling and use4 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 6, 2020 Category: Research Source Type: news
